Table 3. Patient, disease, and treatment... | American Society of Hematology

Table 3.

Patient, disease, and treatment characteristics associated with risk of mortality

Characteristic at start of second-line treatment	Univariate analysis			Multivariable analysis
Characteristic at start of second-line treatment	HR	95% CI	P	HR	95% CI	P
Age at second-line treatment (per decade)	1.34	1.22-1.46	$<$ ⁠.0001	1.22	1.10-1.35	.0002
Weeks from transplant to first treatment (per week)	1.09	1.02-1.16	.007
Bilirubin (per mg/dL)	1.16	1.07-1.26	.0004	1.17	1.07-1.28	.001
Albumin (per g/dL decrease)	2.53	1.96-3.25	$<$ ⁠.0001	1.83	1.30-2.57	.0005
Diarrhea	2.06	1.42-3.00	.0002
Any abdominal pain	2.54	1.80-3.58	$<$ ⁠.0001
Stage 4 gut	3.57	2.42-5.28	$<$ ⁠.0001
No abdominal pain, no stage 4 gut	Ref†	NA	NA	Ref†	NA	NA
Any abdominal pain, no stage 4 gut*	1.81	1.20-2.75	.005	1.17	0.71-1.91	.54
Any abdominal pain with stage 4 gut	4.39	2.86-6.73	<.0001	2.96	1.76-4.98	<.0001
Overt gastrointestinal hemorrhage	4.07	2.04-8.13	$<$ ⁠.0001
HCT-CI (per unit)	1.24	1.14-1.34	$<$ ⁠.0001
Steroid dose (per mg/kg prednisone equivalent)	1.74	1.22-2.47	.002
Skin stage (per stage)	0.83	0.73-0.94	.004
Body surface with rash (per 10%)	0.92	0.87-0.97	.001
Number of prior transplants	1.04	0.70-1.55	.84
Transplant year (per year)	1.04	0.99-1.09	.09
Weeks from first treatment to second treatment (per week)	0.97	0.93-1.01	.16
Fever	0.64	0.26-1.57	.33
Active infection	0.81	0.51-1.26	.35
Agent						Global P = .39
Extracorporeal photopheresis	Ref†	NA	NA	Ref†	NA	NA
α-1 antitrypsin	3.72	1.34-10.35	.01	1.45	0.51-4.14	.49
ATG	4.42	1.73-11.25	.002	1.74	0.66-4.58	.27
Infliximab	2.26	0.76-6.75	.14	1.33	0.43-4.09	.62
Mycophenolate mofetil (not used for prophylaxis)	1.61	0.61-4.23	.34	1.69	0.62-4.64	.31
Sirolimus	1.40	0.52-3.79	.50	1.47	0.54-3.98	.45
Other	3.37	1.29-8.75	.01	2.51	0.95-6.59	.06

Characteristic at start of second-line treatment	Univariate analysis			Multivariable analysis
Characteristic at start of second-line treatment	HR	95% CI	P	HR	95% CI	P
Age at second-line treatment (per decade)	1.34	1.22-1.46	$<$ ⁠.0001	1.22	1.10-1.35	.0002
Weeks from transplant to first treatment (per week)	1.09	1.02-1.16	.007
Bilirubin (per mg/dL)	1.16	1.07-1.26	.0004	1.17	1.07-1.28	.001
Albumin (per g/dL decrease)	2.53	1.96-3.25	$<$ ⁠.0001	1.83	1.30-2.57	.0005
Diarrhea	2.06	1.42-3.00	.0002
Any abdominal pain	2.54	1.80-3.58	$<$ ⁠.0001
Stage 4 gut	3.57	2.42-5.28	$<$ ⁠.0001
No abdominal pain, no stage 4 gut	Ref†	NA	NA	Ref†	NA	NA
Any abdominal pain, no stage 4 gut*	1.81	1.20-2.75	.005	1.17	0.71-1.91	.54
Any abdominal pain with stage 4 gut	4.39	2.86-6.73	<.0001	2.96	1.76-4.98	<.0001
Overt gastrointestinal hemorrhage	4.07	2.04-8.13	$<$ ⁠.0001
HCT-CI (per unit)	1.24	1.14-1.34	$<$ ⁠.0001
Steroid dose (per mg/kg prednisone equivalent)	1.74	1.22-2.47	.002
Skin stage (per stage)	0.83	0.73-0.94	.004
Body surface with rash (per 10%)	0.92	0.87-0.97	.001
Number of prior transplants	1.04	0.70-1.55	.84
Transplant year (per year)	1.04	0.99-1.09	.09
Weeks from first treatment to second treatment (per week)	0.97	0.93-1.01	.16
Fever	0.64	0.26-1.57	.33
Active infection	0.81	0.51-1.26	.35
Agent						Global P = .39
Extracorporeal photopheresis	Ref†	NA	NA	Ref†	NA	NA
α-1 antitrypsin	3.72	1.34-10.35	.01	1.45	0.51-4.14	.49
ATG	4.42	1.73-11.25	.002	1.74	0.66-4.58	.27
Infliximab	2.26	0.76-6.75	.14	1.33	0.43-4.09	.62
Mycophenolate mofetil (not used for prophylaxis)	1.61	0.61-4.23	.34	1.69	0.62-4.64	.31
Sirolimus	1.40	0.52-3.79	.50	1.47	0.54-3.98	.45
Other	3.37	1.29-8.75	.01	2.51	0.95-6.59	.06

HR, hazard ratio; NA, not applicable.

This group also included the 2 patients with no abdominal pain and stage 4 gut involvement because of overt hemorrhage.

†

Reference groups were used as the comparison for other groups.

View Large

This Feature Is Available To Subscribers Only